TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06299358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage
Description: Infants in the foot massage group will receive foot massage by the researcher on two consecutive days of the week for a total of four times. The massage will be performed in accordance with the specified application steps for 10 minutes just before the baby's restlessness starts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother heart sound
Description: The sound recorded by the researcher under appropriate conditions will be played to the babies in the maternal heart sound group from an appropriate distance. The sound will be played a total of four times, on two consecutive days of the week, just before the baby's restlessness begins and for half an hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage and maternal heart sound
Description: Infants in the foot massage and maternal heart sound group will receive foot massage by the researcher on two consecutive days of the week for a total of four times. The massage will be performed in accordance with the specified application steps for 10 minutes just before the baby's restlessness starts. From the beginning of the massage, the pre-recorded maternal heart sound will be played to the infant for 30 minutes from an appropriate distance.
Study: NCT06388642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide 16mg implant
Description: afamelanotide 16mg implant will be administered to each patient during the study.
Study: NCT06096701

Intervention type: DEVICE
Intervention: Blood pressure cuff
Description: The BP cuff is connected in a Health Insurance Portability and Accountability Act-compliant fashion to the patient's medical record, allowing for documentation and communication with the nurse and the care team. Alerts are triggered if a patient has not checked her BP for 3 days or when readings fall outside a specific threshold (high or low BP alerts). Based on these alerts, the nurse follows up with these patients and reminds them to take a reading. The nurse will also notify participants with elevated BP values to repeat their BP and will contact the participants by phone to discuss symptoms and antihypertensive medications. Patients will be managed based on a clinical algorithm for initiation of antihypertensive medications without the need for an outpatient visit if considered appropriate by the clinical provider.
Study: NCT04885270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin i.p.
Description: paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1
Study: NCT05195619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)
Description: Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)
Description: Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Description: Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
Study: NCT06550297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meals and Nutritional Counseling
Description: God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Meals and Nutritional Counseling
Description: God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.
Study: NCT05195619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Description: Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
Study: NCT05946980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component hand hygiene intervention in primary health care facilities
Description: Intervention facilities will receive (1), two novel Gravit'eau (https://www.graviteau.ch/) handwashing systems which are locally produced. These systems recycle water for handwashing with gravity through a membrane filter without electricity up to a month. Facilities also receive (2), a behavior change intervention lead by RANAS (https://www.ranasmosler.com/ranas), expert psychologist for behavior change in WASH. They will also receive (3), support to implement WASH FIT (https://washfit.org/#/) in their facilities, a tool developed by WHO to sustainably maintain and improve WASH infrastructure in health care facilities. Additionally, we are recruiting a circuit rider responsible for the regular inspection and maintenance of WASH infrastructure. (4), the facilities will receive support for regular water chlorination.
Study: NCT05252845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M vaccination
Description: R21/Matrix-M is the standard formulation of the vaccine (Once prepared, a standard dose of R21/Matrix-M contains approximately 5 µg of R21 antigen, in 0.5 mL of liquid adjuvant containing 50 µg MatrixM). The reconstituted vaccine will be administered by slow IM injection on Day 0 at Study Months 0, 1 and 2.
Study: NCT06550297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meals and Nutritional Counseling
Description: God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Promotion Educational Program
Description: Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Health Promotion Educational Program
Description: Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
Study: NCT06550297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Promotion Educational Program
Description: Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
Study: NCT06399003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIBP MMR Vaccine
Description: This is a live attenuated measles, mumps, and rubella combined vaccine (Shanghai MMR) in a freeze-dried powder form, developed and manufactured by Shanghai Institute of Biological Products. A single dose of 0.5 mL, containing not less than 3.0 log CCID50 of both live measles virus and rubella virus and 4.3 log CCID50 of live mumps virus. 0.5ml per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIBP MMR Vaccine
Description: This is a live attenuated measles, mumps, and rubella combined vaccine (Shanghai MMR) in a freeze-dried powder form, developed and manufactured by Shanghai Institute of Biological Products. A single dose of 0.5 mL, containing not less than 3.0 log CCID50 of both live measles virus and rubella virus and 4.3 log CCID50 of live mumps virus. 0.5ml per dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK MMR Vaccine (PRIORIX)
Description: PRIORIX (combined measles, mumps and rubella vaccine, live, attenuated) is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain) and Wistar RA 27/3 rubella strains of viruses, separately obtained by propagation either in chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella). 0.5ml per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine (Stamaril)
Description: This is a live, attenuated, lyophilized yellow fever vaccine manufactured by Sanofi Pasteur Europe, Lyon, France. A single dose of 0.5 mL contains with not less than 1000 IU of yellow fever virus 17D-204 strain. 0.5ml per dose.
Study: NCT04815265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is used for sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine is used for sedation
Study: NCT05252845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-PIP
Description: Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PIP
Description: Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQ
Description: Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ
Description: Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
Study: NCT04766086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Multivalent Group B streptococcus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Multivalent Group B streptococcus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, diphtheria, and acellular pertussis vaccine
Description: Tetanus, diphtheria, and acellular pertussis vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, diphtheria, and acellular pertussis vaccine
Description: Tetanus, diphtheria, and acellular pertussis vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline control

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline control
Study: NCT05285462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Pain Education
Description: pain education delivered via VR headset, up to 12 sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Physical Therapy
Description: Normal course of PT without influence by study team on frequency or duration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Physical Therapy
Description: Normal course of PT without influence by study team on frequency or duration
Study: NCT05553639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-302/HB-301 Alternating 2-Vector Therapy
Description: Alternating Therapy of HB-302 and HB-301. The first 5 doses will be administered every 3 weeks. The 6th dose will be administered 6 weeks after the 5th dose. Subsequent doses will be administered every 6 weeks.
Study: NCT04623073

Intervention type: PROCEDURE
Intervention: Total Hip arthroplasty via a Direct Anterior Approach
Description: Total Hip arthroplasty via a Direct Anterior Approach
Study: NCT05094401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BT-001
Description: BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
Study: NCT05685992

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05885659

Intervention type: OTHER
Group type: OTHER
Intervention: Control group (waiting list)
Description: T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet. Participants assigned to this control group will participate in the scheduled assessments (pre- and post-treatment, 1-month, 6-months and 12-months follow-ups) but without receiving any of the intensive treatments previously described (CBT vs. CBT+DiME-SALUD2 protocol).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT) for smoking cessation
Description: CBT for smoking cessation will be implemented in group-based sessions of four to six patients, once a week over an eight-week period (Becoña, 2007), and includes three different components: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards. This modality of treatment also includes the following components, among others: Therapeutic contract, self-monitoring and graphical representation of tobacco consumption, psychoeducation about tobacco and specific characteristics of smoking behavior, stimulus control, strategies for coping with nicotine withdrawal symptoms, physiological feedback of consumption (using CO and cotinine in urine levels), social reinforcement when meeting nicotine reduction and abstinence goals, training in alternative behaviors to consumption and strategies for the prevention of relapses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for smoking cessation + DiMeSALUD2 protocol
Description: In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation). CBT plus DiMe-SALUD2 protocol will be developed as in the precedent group, but with the addition of a psychoeducational protocol for monitoring nicotine fading and abstinence specifically designed to address the particular needs of T2DM smokers. The main components of this protocol will be focused on strengthening healthy lifestyle habits as well as structured around the following core elements: dietary control and healthy nutrition, physical exercise, and glycemic control through daily self-registration of both glycemic variability and nicotine fading or abstinence. If necessary, the therapist will adapt these guidelines according to the established medical advice that the smokers receive from their own endocrinologist, so that this program is developed in accordance with their usual medical care.
Study: NCT05791448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNA Transcription Modulator AU-409
Description: Given PO
Study: NCT05159401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prevention of respiratory failure
Description: Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prevention of respiratory failure
Description: Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prevention of respiratory failure
Description: Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prevention of respiratory failure
Description: Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue
Study: NCT05526586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Alcohol Gum Prototype
Description: Participants will use 20 mL of Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Gum Prototype
Description: Participants will use 20 mL of Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint Antiseptic Mouthwash
Description: Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% Hydroalcohol
Description: Participants will use 20 mL of 5% Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
Study: NCT05747898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cannula- based subcision
Description: Insertion of a needle into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: common- needle based subcision
Description: Insertion of a cannula into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
Study: NCT05672628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus VR
Description: During the first visit, the Oculus headset will be placed on the stroke survivor's head and demonstrate how to use the headset. participant will be then allowed to play a game using the hand controllers for up to 30 minutes. Finally, a copy of exercises for their home rehabilitation program will be provided. During the next rehabilitation visits, a trained research assistant will guide the stroke survivor with using the gaming headset. The session will be stopped every 20 minutes to make sure that the stroke survivor is feeling well and to give them a break. The stroke survivor may stop the session at any time. This session will last for an hour.